Inflammation and hypertension: The search for a link

Nephrology Dialysis Transplantation

Volumn 21, Issue 4, 2006, Pages 850-853

  Pauletto, Paolo ^a,b   Rattazzi, Marcello ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b OSPEDALE CA FONCELLO   (Italy)

Author keywords

Arterial stiffness; Atherosclerosis; Cytokines; Hypertension; Inflammation; Smooth muscle cells

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CD40 ANTIGEN; CD40 LIGAND; CERULOPLASMIN; FIBRINOGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; OROSOMUCOID; PADGEM PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRYPSIN INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANTIHYPERTENSIVE ACTIVITY; ATHEROGENESIS; BLOOD VESSEL CALCIFICATION; EDITORIAL; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; ESSENTIAL HYPERTENSION; FIBRINOGEN BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INFLAMMATION; METABOLIC SYNDROME X; NONHUMAN; PATHOPHYSIOLOGY; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RISK FACTOR; VASCULAR SMOOTH MUSCLE;

ANIMALS; CYTOKINES; EXTRACELLULAR MATRIX PROTEINS; HUMANS; HYPERTENSION; INFLAMMATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33645300081     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl019     Document Type: Editorial

References (36)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695
3. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004; 109: II2-II10
4. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension 2001; 38: 399-403
5. Schillaci G, Pirro M, Gemelli F et al. Increased C-reactive protein concentrations in never-treated hypertension: The role of systolic and pulse pressures. J Hypertens 2003; 21: 1841-1846
6. Stumpf C, John S, Jukic J et al. Enhanced levels of platelet P-selectin and circulating cytokines in young patients with mild arterial hypertension. J Hypertens 2005; 23: 995-1000
7. Chrysohoou C, Pitsavos C, Panagiotakos DB, Skoumas J, Stefanadis C. Association between prehypertension status and inflammatory markers related to atherosclerotic disease: The ATTICA Study. Am J Hypertens 2004; 17: 568-573
8. Yan JC, Ma GS, Wu ZG, Kong XT, Zong RQ, Zhan LZ. Increased levels of CD40-CD40 ligand system in patients with essential hypertension. Clin Chim Acta 2005; 355: 191-196
9. Engstrom G, Lind P, Hedblad B, Stavenow L, Janzon L, Lindgarde F. Long-term effects of inflammation-sensitive plasma proteins and systolic blood pressure on incidence of stroke. Stroke 2002; 33: 2744-2749
10. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. Jama 2003; 290: 2945-2951
11. Niskanen L, Laaksonen DE, Nyyssonen K et al. Inflammation, abdominal obesity, and smoking as predictors of hypertension. Hypertension 2004; 44: 859-865
12. Grundy SM. Inflammation, hypertension, and the metabolic syndrome. Jama 2003; 290: 3000-3002
13. Sanz-Rosa D, Oubina MP, Cediel E et al. Effect of AT1 receptor antagonism on vascular and circulating inflammatory mediators in SHR: role of NF-kappaB/IkappaB system. Am J Physiol Heart Circ Physiol 2005; 288: H111-H115
14. Capers Qt, Alexander RW, Lou P et al. Monocyte chemoattractant protein-1 expression in aortic tissues of hypertensive rats. Hypertension 1997; 30: 1397-1402
15. Luvara G, Pueyo ME, Philippe M et al. Chronic blockade of NO synthase activity induces a proinflammatory phenotype in the arterial wall: prevention by angiotensin II antagonism. Arterioscler Thromb Vasc Biol 1998; 18: 1408-1416
16. Cheng ZJ, Vapaatalo H, Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit 2005; 11: RA194-RA205
17. Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110: 1103-1107
18. Schieffer B, Bunte C, Witte J et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 2004; 44: 362-368
19. Sartore S, Chiavegato A, Franch R, Faggin E, Pauletto P. Myosin gene expression and cell phenotypes in vascular smooth muscle during development, in experimental models, and in vascular disease. Arterioscler Thromb Vasc Biol 1997; 17: 1210-1215
20. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: Risk marker or mediator in atherothrombosis? Hypertension 2004; 44: 6-11
21. Nilsson J. CRP-marker or maker of cardiovascular disease? Arterioscler Thromb Vasc Biol 2005; 25: 1527-1528
22. Raines EW, Ferri N. Thematic review series: The immune system and atherogenesis. Cytokines affecting endothelial and smooth muscle cells in vascular disease. J Lipid Res 2005; 46: 1081-1092
23. Puato M, Faggin E, Favaretto E et al. Prevalence of fetal-type smooth muscle cells in the media of microvessels from hypertensive patients. Hypertension 2004; 44: 191-194
24. Dernellis J, Panaretou M. Aortic stiffness is an independent predictor of progression to hypertension in nonhypertensive subjects. Hypertension 2005; 45: 426-431
25. Mahmud A, Feely J. Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension 2005; 46: 1118-1122
26. Nagano M, Nakamura M, Sato K, Tanaka F, Segawa T, Hiramori K. Association between serum C-reactive protein levels and pulse wave velocity: A population-based cross-sectional study in a general population. Atherosclerosis 2005; 180: 189-195
27. Yasmin, McEniery CM, Wallace S, Mackenzie IS, Cockcroft JR, Wilkinson IB. C-reactive protein is associated with arterial stiffness in apparently healthy individuals. Arterioscler Thromb Vasc Biol 2004; 24: 969-974
28. Shoji T, Emoto M, Shinohara K et al. Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol 2001; 12: 2117-2124
29. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740
30. Speer MY, Giachelli CM. Regulation of cardiovascular calcification. Cardiovasc Pathol 2004; 13: 63-70
31. Rattazzi M, Bennett BJ, Bea F et al. Calcification of advanced atherosclerotic lesions in the innominate arteries of ApoE-deficient mice: Potential role of chondrocyte-like cells. Arterioscler Thromb Vasc Biol 2005; 25: 1420-1425
32. Giachelli CM, Speer MY, Li X, Rajachar RM, Yang H. Regulation of vascular calcification: Roles of phosphate and osteopontin. Circ Res 2005; 96: 717-722
33. Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 2004; 95: 560-567
34. Johnson RJ, Rodriguez-Iturbe B, Kang DH, Feig DI, Herrera-Acosta J. A unifying pathway for essential hypertension. Am J Hypertens 2005; 18: 431-440
35. Rodriguez-Iturbe B, Quiroz Y, Ferrebuz A, Parra G, Vaziri ND. Evolution of renal interstitial inflammation and NF-kappaB activation in spontaneously hypertensive rats. Am J Nephrol 2004; 24: 587-594
36. Rodriguez-Iturbe B, Ferrebuz A, Vanegas V, Quiroz Y, Mezzano S, Vaziri ND. Early and sustained inhibition of nuclear factor-kappaB prevents hypertension in spontaneously hypertensive rats. J Pharmacol Exp Ther 2005; 315: 51-57